ClinicalTrials.gg
CompletedNCT01201811Updated Dec 5, 2019Results posted

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

A Phase 4 interventional study of Azacitidine in Myelodysplastic Syndromes, sponsored by Celgene. Completed at 11 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-05.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
51st of 126
44 · median 38
Started
2010
with 6 others
Phase 4
3 of 130
1 open now
Registered
41st of 130
by date
Lead sponsor
14 of 130
Celgene

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 51st largest by enrollment of the 126 interventional ones that give a count, is one of 7 that started in 2010, is one of 3 in phase 4, and was the 41st registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine the effectiveness and safety of azacitidine in the treatment of Taiwanese subjects with higher-risk Myelodysplastic Syndrome (MDS).

Read the detailed description

The study has 3 phases which include the Screening Phase, the Treatment Phase, and the Post-Treatment Phase and outlined as follows:

Screening Phase:

Subjects will provide informed consent prior to undergoing any study-related procedures. Screening procedures are to take place within 28 days prior to the initiation of azacitidine treatment (Day 1, Cycle 1). Subject eligibility will be based on central pathology review. Bone marrow aspirate and bone marrow biopsy will be collected at screening and sent for morphological assessment by a central pathology reviewer prior to the subject receiving IP. The central pathology reviewer will document the MDS classification according to the FAB and WHO criteria (Appendix A and B, respectively).

A standard cytogenetic metaphase preparation will be prepared from the bone marrow aspirate and sent to the local or central laboratory (for sites without local analysis capability) for the cytogenetic analysis prior to receiving IP.

The IPSS score will be calculated using the central reviewer's pathology report for bone marrow blast percentage, local cytogenetic assessment for karyotype, and central laboratory report for number of cytopenias (Appendix D).

Treatment Phase:

The first dose of azacitidine for each subject begins on Day 1 of Cycle 1. All subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from treatment. Visits during the treatment phase are to be scheduled weekly for the first 2 cycles, then every other week for all subsequent cycles throughout the rest of the study. Safety and efficacy measures are to be performed weekly, every other week, every 4 weeks, or at 24 weeks, depending on the procedure.

Post-Treatment Phase:

All discontinued subjects, regardless of reason for discontinuation, should undergo end-of-study procedures at the time of study discontinuation. Subjects will have a follow-up visit for the collection of adverse events up to 28 days after last IP dose.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • Myelodysplastic Syndromes
  • Taiwan
  • Azacitidine
  • Vidaza
  • Celgene
  • Pathologic Processes
  • Neoplasms
  • Bone Marrow Diseases
  • Hematologic Diseases
  • Antineoplastic Agents
  • Antimetabolites, Antineoplastic
  • Antimetabolites
  • Molecular Mechanisms of Pharmacological Action
  • Pharmacologic Actions
  • Therapeutic Uses
  • Enzyme inhibitors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of RAEB or RAEB-T according to FAB classification for MDS and with an IPSS score of intermediate-2 or high risk or a diagnosis of myelodysplastic CMML per modified FAB criteria.
  • Taiwanese males and females ≥ 18 years of age
  • 0, 1, or 2;
  • Adequate hepatic and renal organ function

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with azacitidine or decitabine
  • Malignant disease diagnosed within prior 12 months
  • Uncorrected red cell folate deficiency or vitamin B12 deficiency
  • Diagnosis of disease
  • Malignant hepatic tumors
  • Known or suspected to azacitidine or mannitol
  • Prior transplantation or cytotoxic therapy, including azacitidine and chemotherapy, administered to treat MDS
  • Treatment with erythropoietin or myeloid growth factors during the 21 days prior to Day 1 of Cycle 1 or androgenic hormones during the 14 days prior to Day 1 of Cycle 1;
  • Active or viral hepatitis type B or C
  • Treatment with other drugs within the previous 30 days prior to Day 1 of Cycle 1, or ongoing adverse events from previous treatment with investigational drugs, regardless of the time period;
  • Pregnant or lactating females
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Single-Arm

    Azacitidine 75 mg/m\^2/day Subcutaneous for 7 days Day every 28 days for up to 6 cycles

    Drug: Azacitidine

Interventions

  • Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Hematologic Response Using International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Investigator

    Hematologic Response according to the 2000 International Working Group (IWG) response criteria for MDS was based on the Investigators determination and defined as: * Complete Response (CR): repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.5x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia * Partial Response (PR): same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment * Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months. * Failure: death during treatment or disease progression * Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence * Disease Progression: change in blast levels * Disease Transformation to AML

    Time frame: Response assessed at end of cycle 6; through week 24; End of study

  2. Percentage of Participants Showing Hematologic Improvement Using International Working Group (IWG Criteria for Hematologic Improvement Cheson 2000) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Sponsor

    Hematologic improvements (HI) have 4 categories: 1. Erythroid response (HI-E): Major \>20g/L increase or transfusion independent. Minor- 10-20g/L increase or ≥50% decrease in transfusion requirements. 2. Platelet response (HI-P): Major absolute increase of ≥30x10\^9/L or platelet transfusion independence. Minor-≥50% increase. 3. Neutrophil response (HI-N): Major 100% increase or an absolute increase of \>0.5x10\^9/L. Minor-≥100% increase and absolute increase of \<0.5x10\^9/L 4. Progression or relapse after HI Overall hematological improvement (HI) was defined as any type (major or minor) of improvement of HI-E, HI-P, or HI-N. Criteria: Pretreatment=hemoglobin \<100g/L or RBC transfusion-dependent, platelet count \<100x10\^9/L or platelet transfusion dependent, absolute neutrophil count \<1.5x10\^9/L. Sponsor's determination was derived using clinically relevant data. Denominator for progression/relapse after HI included participants who had achieved HI.

    Time frame: Response assessed at end of cycle 6; through week 24; End of study

Secondary outcomes

  1. Number of Red Blood Cell (RBC) Transfusions by Cycle

    The number of transfusions received 56 days prior to treatment and during study were standardized per 28 days and summarized by cycle for RBCs. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length. For each participant the overall post-baseline average was calculated as the average of # of RBC transfusions per cycle.

    Time frame: Up to week 24;The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.

  2. Number of Platelet Transfusions by Cycle

    The number of transfusions received 56 days prior to treatment and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length. For each participant the overall post-baseline average was calculated as the average of # of platelet transfusions per cycle.

    Time frame: Up to week 24; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.

  3. Number of Infections (Post-baseline Average) Requiring Intravenous Antibiotics, Anti-fungals, or Antivirals Per 28 Days

    The on-treatment adverse event of infection requiring IV antibiotics, antifungals, or antivirals per 28 days/cycle. The overall post-baseline average is the average of number of infections requiring IV antibiotics or IV antiviral per 28 days/cycle. For each participant the overall post-baseline average was calculated as the average of # of infections requiring IV antibiotics or IV antiviral per 28 days per cycle.

    Time frame: Up to week 24; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.

  4. Number of Participants With Adverse Events (AE)

    An AE that resulted in any of the following outcomes was defined as a serious adverse event (SAE): * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Treatment Emergent AEs (TEAE) were defined as AEs with an onset date on or after the first dose of study drug and within 28 days after the date of the last dose. In addition, any AE that occurred beyond this timeframe and that was assessed by the investigator as possibly related to study drug was considered a TEAE.

    Time frame: From the first dose of study drug through 28 days after completion of/discontinuation from the study (maximum time on study drug 244 days)

  5. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine

    Area under the plasma concentration-time curve from time zero to infinity (AUC∞) following multiple doses of Azacitidine on Day 7; if possible, the area under the concentration-time curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity was calculated according to the following equation: AUC∞ = AUCt + (Ct/ λz ), where Ct is the last quantifiable concentration. No AUC extrapolation was performed with unreliable λz. If % AUC extrapolated is ≥ 25%, AUC∞ was not reported.

    Time frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

  6. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine

    Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.

    Time frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

  7. Maximum Observed Plasma Concentration (Cmax) of Azacitidine

    The observed maximum plasma concentration obtained directly from the observed concentration versus time data.

    Time frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

  8. Time to Maximum Plasma Concentration (Tmax) of Azacitidine

    Time to maximum observed plasma concentration obtained directly from the observed concentration versus time data.

    Time frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

  9. Terminal Phase of Half-life (T1/2) of Azacitidine

    The apparent terminal half-life was calculated according to the following equation t½ = 0.693/λz.

    Time frame: Timeframe: Day 7 pre-dose at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

  10. Apparent Total Plasma Clearance (CL/F) of Azacitidine

    Apparent total plasma clearance (CL/F) of Azacitidine was calculated as Dose/AUC∞

    Time frame: Timeframe: Days 5 and 6 at predose and Day 7 (pre-dose) at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

  11. Apparent Volume of Distribution (Vd/F) of Azacitidine

    Apparent volume of distribution, was calculated according to the equation: Vd/F = (CL/F)/λz

    Time frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

Other outcomes

  1. Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline

    A participant was considered transfusion dependent at baseline if the participant had one or more Red Blood Cell transfusions during the 56 days prior to first dose. During the study, a participant was considered transfusion independent during the on-treatment period if the participant had no transfusions during any 56 consecutive days or more (e.g., Day 1 through 56, Day 2 through 57, etc). Otherwise, they were considered transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: RBC dependent at BL=32, RBC independent at BL=12)

    Time frame: Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit

  2. Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline

    A participant was considered RBC transfusion-independent at baseline if the participant had no RBC transfusions during the 56 days prior to first dose. During the study, a participant was considered transfusion independent during the on-treatment period if the participant had no RBC transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: RBC dependent at BL=32, RBC independent at BL=12)

    Time frame: Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.

  3. Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline

    A participant was considered platelet transfusion dependent at baseline if the participant had one or more platelet transfusions during the 56 days prior to first dose. During the study, a participant was considered platelet transfusion independent during the on-treatment period if the participant had no platelet transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered platelet transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: platelet dependent at BL=18, platelet independent at BL=26)

    Time frame: Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.

  4. Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline

    A participant was considered platelet transfusion independent at baseline if the participant had no platelet transfusions during the 56 days prior to first dose. During the study, a participant was considered platelet transfusion independent during the on-treatment period if the participant had no platelet transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered platelet transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: platelet dependent at BL=18, platelet independent at BL=26)

    Time frame: Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.

07

Results

Posted Jun 24, 2014

Participant flow

The study was conducted at nine investigational sites within Taiwan. The purpose of the current study was to evaluate the efficacy, safety, and steady-state Pharmacokinetic (PK) profile of subcutaneous (SC) azacitidine given at a dose of 75 mg/m\^2/day for 7 days in Taiwanese participants with higher-risk Myelodysplastic Syndrome (MDS).

Participant flow — Overall Study
MilestoneAzacitidine
Started44
Completed25
Not completed19
Withdrew: Adverse event6
Withdrew: Disease progression3
Withdrew: Withdrawal by subject3
Withdrew: Death4
Withdrew: Treatment failure2
Withdrew: Physician decision1

Outcome measures

PrimaryPercentage of Participants With a Hematologic Response Using International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Investigator

Hematologic Response according to the 2000 International Working Group (IWG) response criteria for MDS was based on the Investigators determination and defined as: * Complete Response (CR): repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.5x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia * Partial Response (PR): same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment * Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months. * Failure: death during treatment or disease progression * Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence * Disease Progression: change in blast levels * Disease Transformation to AML

Time frame:
Response assessed at end of cycle 6; through week 24; End of study
Reported as:
Number · percentage of participants
Percentage of Participants With a Hematologic Response Using International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Investigator
percentage of participantsAzacitidine
Overall (CR+PR)0 (0.0 to 8.0)
Overall (CR+PR+SD)63.6 (47.8 to 77.6)
Complete Remission (CR)0.0 (0.0 to 8.0)
Partial Remission (PR)0.0 (0.0 to 8.0)
Stable Disease (SD)63.6 (47.8 to 77.6)
Disease Progression (DP)2.3 (0.1 to 12.0)
Transformation to AML4.5 (0.6 to 15.5)
Failure4.5 (0.6 to 15.5)
No Response Assessed25.0 (13.2 to 40.3)
PrimaryPercentage of Participants Showing Hematologic Improvement Using International Working Group (IWG Criteria for Hematologic Improvement Cheson 2000) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Sponsor

Hematologic improvements (HI) have 4 categories: 1. Erythroid response (HI-E): Major \>20g/L increase or transfusion independent. Minor- 10-20g/L increase or ≥50% decrease in transfusion requirements. 2. Platelet response (HI-P): Major absolute increase of ≥30x10\^9/L or platelet transfusion independence. Minor-≥50% increase. 3. Neutrophil response (HI-N): Major 100% increase or an absolute increase of \>0.5x10\^9/L. Minor-≥100% increase and absolute increase of \<0.5x10\^9/L 4. Progression or relapse after HI Overall hematological improvement (HI) was defined as any type (major or minor) of improvement of HI-E, HI-P, or HI-N. Criteria: Pretreatment=hemoglobin \<100g/L or RBC transfusion-dependent, platelet count \<100x10\^9/L or platelet transfusion dependent, absolute neutrophil count \<1.5x10\^9/L. Sponsor's determination was derived using clinically relevant data. Denominator for progression/relapse after HI included participants who had achieved HI.

Time frame:
Response assessed at end of cycle 6; through week 24; End of study
Reported as:
Number · percentage of participants
Percentage of Participants Showing Hematologic Improvement Using International Working Group (IWG Criteria for Hematologic Improvement Cheson 2000) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Sponsor
percentage of participantsAzacitidine
Any improvement50.0 (34.6 to 65.4)
Hematologic Improvement-E (major)31.8 (18.6 to 47.6)
Hematologic Improvement-E (minor)9.1 (2.5 to 21.7)
Hematologic Improvement-P (major)37.8 (22.5 to 55.2)
Hematologic Improvement-P (minor)0 (0 to 9.5)
Hematologic Improvement-N (major)7.1 (0.9 to 23.5)
Hematologic Improvement-N (minor)0 (0 to 12.3)
Progression/relapse after HI27.3 (10.7 to 50.2)
Other pre-specifiedParticipants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline

A participant was considered transfusion dependent at baseline if the participant had one or more Red Blood Cell transfusions during the 56 days prior to first dose. During the study, a participant was considered transfusion independent during the on-treatment period if the participant had no transfusions during any 56 consecutive days or more (e.g., Day 1 through 56, Day 2 through 57, etc). Otherwise, they were considered transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: RBC dependent at BL=32, RBC independent at BL=12)

Time frame:
Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit
Reported as:
Number · percentage of participants
Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
percentage of participantsAzacitidine
Baseline Dependent: On-Treatment Independent37.5 ± 1.97
Baseline Dependent; On-Treatment Dependent62.5 ± 2.47
Other pre-specifiedParticipants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline

A participant was considered RBC transfusion-independent at baseline if the participant had no RBC transfusions during the 56 days prior to first dose. During the study, a participant was considered transfusion independent during the on-treatment period if the participant had no RBC transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: RBC dependent at BL=32, RBC independent at BL=12)

Time frame:
Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.
Reported as:
Number · percentage of participants
Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline
percentage of participantsAzacitidine
Baseline Independent; On-Treatment Independent75.0 (42.8 to 94.5)
Baseline Independent; On-Treatment Dependent25.0 (5.5 to 57.2)
SecondaryNumber of Red Blood Cell (RBC) Transfusions by Cycle

The number of transfusions received 56 days prior to treatment and during study were standardized per 28 days and summarized by cycle for RBCs. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length. For each participant the overall post-baseline average was calculated as the average of # of RBC transfusions per cycle.

Time frame:
Up to week 24;The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.
Reported as:
Mean · Transfusions
Number of Red Blood Cell (RBC) Transfusions by Cycle
TransfusionsAzacitidine
Baseline (N = 44)1.3 ± 1.97
Overall Post-Baseline Average (N = 44)2.4 ± 2.47
overall Change from Baseline ( N = 44)1.0 ± 2.59
Cycle 1 ( N = 44)2.5 ± 2.27
Cycle 22.3 ± 2.03
Cycle 32.2 ± 2.90
Cycle 41.5 ± 2.11
Cycle 51.4 ± 2.59
Cycle 61.9 ± 3.96
Other pre-specifiedParticipants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline

A participant was considered platelet transfusion dependent at baseline if the participant had one or more platelet transfusions during the 56 days prior to first dose. During the study, a participant was considered platelet transfusion independent during the on-treatment period if the participant had no platelet transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered platelet transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: platelet dependent at BL=18, platelet independent at BL=26)

Time frame:
Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.
Reported as:
Number · percentage of participants
Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
percentage of participantsAzacitidine
Baseline Dependent; On-Treatment Independent38.9 (17.3 to 64.3)
Baseline Dependent; On-Treatment Dependent61.1 (35.7 to 82.7)
Other pre-specifiedParticipants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline

A participant was considered platelet transfusion independent at baseline if the participant had no platelet transfusions during the 56 days prior to first dose. During the study, a participant was considered platelet transfusion independent during the on-treatment period if the participant had no platelet transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered platelet transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: platelet dependent at BL=18, platelet independent at BL=26)

Time frame:
Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.
Reported as:
Number · percentage of particpants
Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline
percentage of particpantsAzacitidine
Baseline Independent: On-Treatment Independent76.9 (56.4 to 91.0)
Baseline Independent; On-Treatment Dependent23.1 (9.0 to 43.6)
SecondaryNumber of Platelet Transfusions by Cycle

The number of transfusions received 56 days prior to treatment and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length. For each participant the overall post-baseline average was calculated as the average of # of platelet transfusions per cycle.

Time frame:
Up to week 24; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.
Reported as:
Mean · Transfusions
Number of Platelet Transfusions by Cycle
TransfusionsAzacitidine
Baseline ( N = 44)0.9 ± 2.40
Overall Post-Baseline Average ( N= 44)2.7 ± 3.56
OverallChange from Baseline ( N = 44)1.8 ± 3.53
Cycle 1 ( N = 44)2.6 ± 3.38
Cycle 22.3 ± 3.28
Cycle 33.0 ± 4.85
Cycle 41.6 ± 2.89
Cycle 51.9 ± 3.61
Cycle 62.7 ± 6.01
SecondaryNumber of Infections (Post-baseline Average) Requiring Intravenous Antibiotics, Anti-fungals, or Antivirals Per 28 Days

The on-treatment adverse event of infection requiring IV antibiotics, antifungals, or antivirals per 28 days/cycle. The overall post-baseline average is the average of number of infections requiring IV antibiotics or IV antiviral per 28 days/cycle. For each participant the overall post-baseline average was calculated as the average of # of infections requiring IV antibiotics or IV antiviral per 28 days per cycle.

Time frame:
Up to week 24; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.
Reported as:
Mean · Infections per cycle
Number of Infections (Post-baseline Average) Requiring Intravenous Antibiotics, Anti-fungals, or Antivirals Per 28 Days
Infections per cycleAzacitidine
Baseline0.1 ± 0.51
Overall Post Baseline0.5 ± 0.79
Overall Change from Baseline0.4 ± 0.98
Cycle 10.5 ± 0.85
Cycle 20.4 ± 0.61
Cycle 30.4 ± 0.82
Cycle 40.1 ± 0.39
Cycle 50.1 ± 0.38
Cycle 60.2 ± 0.66
SecondaryNumber of Participants With Adverse Events (AE)

An AE that resulted in any of the following outcomes was defined as a serious adverse event (SAE): * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Treatment Emergent AEs (TEAE) were defined as AEs with an onset date on or after the first dose of study drug and within 28 days after the date of the last dose. In addition, any AE that occurred beyond this timeframe and that was assessed by the investigator as possibly related to study drug was considered a TEAE.

Time frame:
From the first dose of study drug through 28 days after completion of/discontinuation from the study (maximum time on study drug 244 days)
Reported as:
Number · participants
Number of Participants With Adverse Events (AE)
participantsAzacitidine
≥ 1 TEAE44
≥ 1 NCI Grade 3 or 4 TEAE37
≥ TEAE related to study drug34
≥ 1 NCI Grade 3 or 4 TEAE related to study drug22
≥ 1 serious TEAE28
≥ 1 NCI CTC Grade 3 or 4 serious TEAE24
≥ 1 serious TEAE related to study drug14
TEAE leading to discontinuation of study drug8
TEAE leading to study drug dose reduction7
TEAE leading to study drug dose interruption16
TEAE leading to dose reduction or interruption20
TEAE leading to death7
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine

Area under the plasma concentration-time curve from time zero to infinity (AUC∞) following multiple doses of Azacitidine on Day 7; if possible, the area under the concentration-time curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity was calculated according to the following equation: AUC∞ = AUCt + (Ct/ λz ), where Ct is the last quantifiable concentration. No AUC extrapolation was performed with unreliable λz. If % AUC extrapolated is ≥ 25%, AUC∞ was not reported.

Time frame:
Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine
ng*h/mLAzacitidine
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine859.1 ± 23.4
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine

Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.

Time frame:
Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine
ng*h/mLAzacitidine
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine852.8 ± 23.3
SecondaryMaximum Observed Plasma Concentration (Cmax) of Azacitidine

The observed maximum plasma concentration obtained directly from the observed concentration versus time data.

Time frame:
Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Azacitidine
ng/mLAzacitidine
Maximum Observed Plasma Concentration (Cmax) of Azacitidine972.3 ± 44.0
SecondaryTime to Maximum Plasma Concentration (Tmax) of Azacitidine

Time to maximum observed plasma concentration obtained directly from the observed concentration versus time data.

Time frame:
Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Reported as:
Geometric mean · hours
Time to Maximum Plasma Concentration (Tmax) of Azacitidine
hoursAzacitidine
Time to Maximum Plasma Concentration (Tmax) of Azacitidine0.29 ± 27.65
SecondaryTerminal Phase of Half-life (T1/2) of Azacitidine

The apparent terminal half-life was calculated according to the following equation t½ = 0.693/λz.

Time frame:
Timeframe: Day 7 pre-dose at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Reported as:
Geometric mean · hours
Terminal Phase of Half-life (T1/2) of Azacitidine
hoursAzacitidine
Terminal Phase of Half-life (T1/2) of Azacitidine1.0 ± 38.7
SecondaryApparent Total Plasma Clearance (CL/F) of Azacitidine

Apparent total plasma clearance (CL/F) of Azacitidine was calculated as Dose/AUC∞

Time frame:
Timeframe: Days 5 and 6 at predose and Day 7 (pre-dose) at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Reported as:
Geometric mean · L/hr
Apparent Total Plasma Clearance (CL/F) of Azacitidine
L/hrAzacitidine
Apparent Total Plasma Clearance (CL/F) of Azacitidine149.6 ± 29.6
SecondaryApparent Volume of Distribution (Vd/F) of Azacitidine

Apparent volume of distribution, was calculated according to the equation: Vd/F = (CL/F)/λz

Time frame:
Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vd/F) of Azacitidine
LitersAzacitidine
Apparent Volume of Distribution (Vd/F) of Azacitidine205.3 ± 32.4

Adverse events

Collected over From the first dose of study drug through 28 days after completion of/discontinuation from the study (maximum time on study drug 244 days). Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azacitidine—28/44 (63.6%)44/44 (100%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventAzacitidine
Febrile neutropeniaBlood and lymphatic system disorders10/44
PneumoniaInfections and infestations8/44
PyrexiaGeneral disorders6/44
SepsisInfections and infestations4/44
NeutropeniaBlood and lymphatic system disorders3/44
Haemorrhage intracranialNervous system disorders3/44
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/44
ThrombocytopeniaBlood and lymphatic system disorders2/44
CellulitisInfections and infestations2/44
Postoperative wound infectionInfections and infestations2/44
Most frequent other events
Showing 10 of 67
Most frequent other events
EventAzacitidine
NeutropeniaBlood and lymphatic system disorders23/44
PyrexiaGeneral disorders23/44
CoughRespiratory, thoracic and mediastinal disorders22/44
AnaemiaBlood and lymphatic system disorders19/44
LeukopeniaBlood and lymphatic system disorders19/44
ConstipationGastrointestinal disorders17/44
DiarrhoeaGastrointestinal disorders17/44
NauseaGastrointestinal disorders17/44
VomitingGastrointestinal disorders17/44
DizzinessNervous system disorders17/44

Baseline characteristics

The intention-to-treat (ITT) population was defined as all enrolled participants.

Age, Continuous
Age, Continuous(years)Azacitidine
Mean62.3 ± 11.76
Sex: Female, Male
Sex: Female, Male(Participants)Azacitidine
Female17
Male27
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Azacitidine
Asian44
Myelodysplastic Syndrome (MDS) French-American-British (FAB) Classification
Myelodysplastic Syndrome (MDS) French-American-British (FAB) Classification(Participants)Azacitidine
Refractory anemia with excess blasts (RAEB)35
RAEB in transformation7
Chronic myelomonocytic leukemia (Modified CMML)2
Acute myelogenous leukemia (AML)0
World Health Organization (WHO) Classification
World Health Organization (WHO) Classification(Participants)Azacitidine
Refractory anemia with excess blasts (RAEB-1)15
Refractory anemia with excess blasts (RAEB-2)23
Acute myelogenous leukemia (AML)5
Chronic myelomonocytic leukemia (CMML -1)1
Chronic myelomonocytic leukemia (CMML-2)0
Refractory anemia (RA)0
RA with ringed sideroblasts (RARS)0
Refractory Cytopenia Multilineage Dysplasia (RCMD)0
Myelodysplastic Syndrome - Unclassified (MDS-U)0
International Prognostic Scoring System (IPSS)
International Prognostic Scoring System (IPSS)(Participants)Azacitidine
Low risk (0)0
Intermediate-1 (0.5 - 1.0)2
Intermediate-2 (1.5 - 2.0)16
High Risk (≥ 2.5)26
08

Study locations

11 sites
  • Changhua Christian Hospital
    Changhua, 500, Taiwan
  • Chiayi Chang Gung Memorial Hospital
    Chiayi, 613, Taiwan
  • Buddhist Tzu Chi General Hospital-Hualien Tzu Chi Medical Center
    Hualien, 970, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung City, 833, Taiwan
  • Kaohsiung Medical Hospital University
    Kaohsiung, 807, Taiwan
  • Shuang-ho Hospital
    New Taipei City, 23561, Taiwan
  • China Medical University Hospital
    Taichung, 404, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Tri-Service General Hospital
    Taipei, 11490, Taiwan
09

References and documents

Publications

  • Chou WC, Yeh SP, Hsiao LT, Lin SF, Chen YC, Chen TY, Laille E, Galettis A, Dong Q, Songer S, Beach CL. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes. Asia Pac J Clin Oncol. 2017 Oct;13(5):e430-e439. doi: 10.1111/ajco.12659. Epub 2017 Jan 25. PubMed 28124500 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2010 to primary completion in May 2013, 31 months.

Results were first posted in Jun 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2010
First posted
Sep 15, 2010
StartActual
Oct 1, 2010
Primary completionActual
May 1, 2013
CompletionActual
May 1, 2013
Results first posted
Jun 24, 2014
Last update
Dec 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01201811
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Sep 15, 2010
Start date
Oct 1, 2010
Primary completion
May 1, 2013
Completion
May 1, 2013
Results posted
Jun 24, 2014
Last update
Dec 5, 2019

Study contacts

C L Beach, PharmD
study director · Celgene

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion